Inventor · disambiguated record
Joshua I. Park
Also filed as: PARK JOSHUA · PARK JOSHUA I · PARK JOSHUA INSHIK
7 granted patents·4 pending applications·66 citations·filing 2006–2024
84Inventor score
Top patents by PatentIndex Score
11 records- 0195US11124567B2Anti-TREM2 antibodies and methods of use thereofDENALI THERAPEUTICS INC·Filed 2021·Granted Sep 21, 2021·16 cites·31 claims
- 0292US9803182B2Ionic liquid-tolerant cellulase enzymesUNIV CALIFORNIA·Filed 2015·Granted Oct 31, 2017·11 cites·15 claims
- 0391US7723472B2Extracellular matrix binding chimeric proteins and methods of use thereofUNIV CALIFORNIA·Filed 2006·Granted May 25, 2010·25 cites·8 claims
- 0487US10378000B2Ionic liquid-tolerant cellulase enzymesUNIV CALIFORNIA·Filed 2017·Granted Aug 13, 2019·3 cites·10 claims
- 0585US9624482B2Thermophilic cellobiohydrolaseSAPRA RAJAT·Filed 2010·Granted Apr 18, 2017·10 cites·30 claims
- 0679US12240902B2Anti-TREM2 antibodies and methods of use thereofDENALI THERAPEUTICS INC·Filed 2021·Granted Mar 4, 2025·1 cites·20 claims
- 0766US2025333528A1Transferrin receptor-binding domains and proteins comprising the sameDENALI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0863US2025000991A1Nectin-4 antibodies and antibody-drug conjugatesLILLY CO ELI·Filed 2024·Application pending·0 cites
- 0962US2022177576A1Anti-trem2 antibodies and methods of use thereofDENALI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1061US2024299575A1Oligonucleotide conjugates targeted to the transferrin receptorDENALI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1144US12049511B2Engineered CD46-specific effector cells and uses thereof in the treatment of cancerFORTIS THERAPEUTICS INC·Filed 2017·Granted Jul 30, 2024·0 cites·19 claims
Join the waitlist — get patent alerts
Get an alert when Joshua I. Park files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →